CD47 and glioblastoma: The therapeutic use of CD47 blockade combined with either temozolomide or irradiation enhanced its effects by increasing macrophage-mediated phagocytosis of GBM cells, resulting in an increased survival rate of GBM-implanted mice and a significant inhibition of tumor growth.